Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma

• Hauptverfasser: Tianzi Wei (Verfasst von), Risheng Lin (Verfasst von), Xing Fu (Verfasst von), Yi Lu (Verfasst von), Weiwen Zhang (Verfasst von), Zhengxuan Li (Verfasst von), Jian Zhang (Verfasst von), Hao Wang (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2022-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Sorafenib, a multikinase inhibitor, has been widely used as a first-line anticancer drug for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance to sorafenib is frequently observed in clinical applications. Potential nonkinase targets of sorafenib have not been well...